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Abstract During the last decade a tremendous technologic
progress based on genome-wide profiling of genetic aberra-
tions, structural DNA alterations, and sequence variations
has allowed a better understanding of the molecular basis of
pediatric and adult B/T- acute lymphoblastic leukemia
(ALL), contributing to a better recognition of the biological
heterogeneity of ALL and to a more precise definition of
risk factors. Importantly, these advances identified novel
potential targets for therapeutic intervention. This review
will be focused on the cytogenetic/molecular advances in
pediatric and adult ALL based on recently published
articles.
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Introduction
ALL represents a biologically and clinically heteroge-
neous group of B/T-precursor-stage lymphoid cell ma-
lignancies arising from genetic insults that block
lymphoid differentiation and drive aberrant cell
proliferation and survival. Incidence and cure rates dif-
fer among children and adults. In children, ALL is the
commonest malignancy accounting for approximately
25 % of childhood cancer and it has 5-year event-free
survival rates ranging between 76 % and 86 % in
patients receiving protocol-based therapy. In adults,
ALL is less common and generally carries a worse
prognosis with a long-term survival probability less than
35–40 % [1, 2]. Although there is remarkable progress
made in the treatment of ALL in children and, with less
efficacy, in adults, several ALL subtypes continue to
have a poor prognosis and in a proportion of long-
term surviving patients, treatment is responsible for
short and long-term toxicities. Consequently, there is a
need in improving the molecular dissection of subtypes,
identifying genetic alterations that predict the risk of
treatment failure, and developing novel and targeted
therapies. Cytogenetics has long been used for diagno-
sis, risk stratification, and therapeutic implications, how-
ever experimental models [3, 4] have established that
primary cytogenetic abnormalities alone are insufficient
to induce leukemia and that cooperative mutations are
required. The development of microarray technologies to
profile gene expression and structural genetic alterations
in a genome-wide and high-resolution fashion have rev-
olutionized our ability to identify genetic abnormalities
providing important insights into the pathways deregu-
lated in ALL [5]. Moreover, recently the development
of next-generation sequencing (NGS) technologies has
provided researchers with completely new and effective
tools for the discovery of novel alterations, depicting an
exhaustive picture of the leukemia genome complexity
(Fig. 1). This review emphasizes the most important and
newest findings obtained from genomic analysis of B/T-
lineage ALL.
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B-Progenitor Acute Lymphoblastic Leukemia
Prognostic Factors Based on Cytogenetics
Cytogenetics and fluorescence in situ hybridization (FISH)
reveal recurring chromosome abnormalities, including numer-
ical and structural changes, in approximately 80 % of ALL.
Substantial differences in the frequencies of some recurring
abnormalities are present between children and adults.
& The t(8;14)[MYC-IgH], present in a high proportion of
Burkitt cell leukemia/lymphoma, occurs in approximately
1 % of adults. This translocation is associated with
French-American-British (FAB)-L3-type leukemia cells,
high incidence of central nervous system involvement at
diagnosis, and poor prognosis [6].
& The t(4;11)[MLL-AF4] is present in up to 60 % of
infants younger than 12 months, but is rarely observed
in adult patients. This translocation is associated with
FAB L1 or L2 morphology, immature immunopheno-
type, B-cell lineage, frequent co-expression of myeloid
antigens, and high leukocyte counts. The prognosis is
poor in both adults and children [7, 8].
& The t(9;22)[BCR-ABL1] that produces the Philadelphia
(Ph) chromosome is observed in about 2 % to 5 % of
children and 30 % of adults. This translocation is associ-
ated with a dismal prognosis. Treatment with tyrosine
kinase inhibitors (TKIs) has produced promising results,
althoughwith the passage of time, problems have emerged
with drug resistance and disease persistence [9].
& The t(1;19)[TCF3-PBX1] occurs in approximately 30 %
of pre-B cell childhood ALL patients. In the past,
patients with the t(1;19) typically had early treatment
failure. However, this adverse prognosis can be
overcome by more intensive chemotherapy such that
the t(1;19) is now associated with a favorable prognosis
[10, 11].
& The t(12;21)[ETV6-RUNX1] is detectable by FISH or
polymerase chain reaction analysis in about 25 % of
children and 3 % of adults with B-ALL. Patients gener-
ally have a favorable prognosis [12].
& Patients with hyperdiploidy with more than 50 chromo-
somes often have a good prognosis. The individual
structural abnormalities do not appear to influence
outcome in patients with hyperdiploidy except for
the t(9;22), which is associated with a poor progno-
sis [13].
& Approximately 5 % to 6 % of ALL patients, independent
of age, have clonal loss of various chromosomes, resulting
in a hypodiploid clone with fewer than 46 chromosomes.
These patients generally have a poor prognosis, especially
those with near-haploid and low-hypodiploid clones.
Similarly, deletion of 9p is an unfavorable risk factor
associated with a high rate of relapse in B-precursor
ALL in children [14].
Prognostic Factors Based on Genomic Profiling
The advent of high-resolution genome-wide analyses of
gene expression, DNA copy number alterations (CNA),
and loss of heterozygosity have led to the detection of many
novel genetic abnormalities refining the prognostic models
for ALL (Table 1). Using single nucleotide polymorphism
(SNP) arrays, many groups detected multiple submicroscopic
CNA not evident on cytogenetic analysis, commonly less than
one megabase (Mb) in size and targeting, in most of the cases,
a single or few genes implicated in key cellular pathways,
Fig. 1 Next-generation sequencing (NGS) in B/T ALL. Whole ge-
nome/exome/transcriptome sequencing approaches provide a compre-
hensive view of the landscape of genetic alterations in leukemia
allowing the identification of potential novel markers for diagnosis,
risk-stratification, and tailored treatments. Here, studies using NGS
approaches in B/T ALL are schematized
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such as lymphoid development (IKZF1, PAX5, EBF1,
VPREB1), cell cycle regulation and tumor suppression
(CDKN2A/CDKN2B, PTEN, BTG1, RB1), lymphoid signal-
ing (BTLA, CD200), drug responsiveness (NR3C1), and DNA
mismatch repair (MTOR, HERC1, PRKCZ, and PIK3C2B) [5,
15–17, 18•, 19, 20]. Importantly, there were substantial differ-
ences in the frequency and nature of CNAs among various
disease subtypes.MLL-rearranged leukemias harbor less than
one CNA per case, suggesting thatMLL is a potent oncogene
that requires very few cooperating lesions to induce leukemia
transformation. In contrast, ETV6-RUNX1 and BCR-ABL1
rearranged leukemias harbor six to eight alterations per case
that may be present years after the initial chromosome
rearrangements, indicating that these additional postnatal
genetic alterations are required to induce the full leukemic
phenotype [5].
Genetic Alterations in B-Lymphoid Development Genes
Over two-thirds of genetic abnormalities affected genes
involved in lymphoid development. These alterations in-
clude deletions, focal amplifications, novel translocations,
and point mutations involving transcriptional regulators of
early B-cell lineage development, such as IKZF1 (Ikaros),
PAX5 (Paired box 5), EBF1 (early B-cell factor), LEF1
(lymphoid enhancer factor 1), and immunoglobulin family
genes, such as VPREB1 (pre-B lymphocyte 1).
IKZF1 Ikaros is a DNA-binding zinc finger transcription
factor that regulates the development and function of the
immune system and acts as a master regulator of normal
hematopoietic differentiation and proliferation, particularly
in lymphoid lineages [21]. During the last 5 years, IKZF1
has been established as one of the most clinically relevant
tumor suppressors in ALL. Deletion of a single IKZF1 allele
or mutations of a single copy of IKZF1 were firstly detected
in 15 % of all cases of pediatric B-cell ALL and in more
than 80 % of Ph+lymphoid leukemia cases, either de novo
Ph+ ALL or chronic myeloid leukemia at progression to
lymphoid blast crisis [15, 22, 23]. By contrast, IKZF1 alter-
ations were uncommon in other ALL subtypes that other-
wise harbor multiple DNA copy-number alterations, such as
ETV6-RUNX1 ALL, suggesting that IKZF1 alteration is a
key determinant of the lineage and progression of Ph+
leukemia. The analysis of a twin pair concordant for ALL
showed that in childhood Ph+ ALL, BCR-ABL1 gene fusion
can be a prenatal and possibly initiating genetic event
whereas deletion of IKZF1 is a secondary and probable
postnatal mutation that is associated with poor prognosis
[24]. The deletions either involve the entire IKZF1 lo-
cus, resulting in loss of function, or delete an internal
subset of IKZF1 exons, resulting in the expression of
dominant negative IKZF1 alleles. Expression of such
dominant negative IKZF1 alleles in hematopoietic pro-
genitors impairs lymphoid development [25], and loss of
IKZF1 accelerates the onset of Ph+ ALL in a retroviral
Table 1 Novel recurring genetic alterations occurring in B-progenitor ALL and their correlation with outcome
Gene name Genetic alteration Frequency Prognosis References
IKZF1 Deletions or sequence mutations ~80 % of BCR-ABL1 positive
ALL; 15 % of pediatric
B-ALL cases
Associated with poor outcome [5, 27–31]
PAX5 Deletions, sequence mutations
or translocations
~30 % of pediatric and
adult B-ALL
No association with outcome [17, 29, 35]
CDKN2A/B Deletions ~30 % of pediatric and adult
B-ALL; 47 % of relapsed
BCR-ABL1-ALL
Associated with poor outcome in








Up to 16 % of pediatric and
adult B-ALL; >50 %
Down syndrome ALL
Associated with poor outcome [40–43]
JAK1/2 Sequence mutations ~10 % of high-risk BCR-
ABL1-like ALL and
18–35 % of Down
syndrome ALL
Associated with poor outcome [40–43]
CREBBP Deletions and sequence mutation 19 % of relapsed B-ALL Associated with glucocorticoid
resistance
[54•]
iAMP21 Intrachromosomal amplification Up to 2 % in older children
with B- ALL
Associated with poor outcome when
patients are treated with standard
therapy
[50, 51]
TP53 Deletions and sequence mutations 12.4 % of B-ALL Associated with non-response to
chemotherapy and poor event-free
survival and overall survival rates
[56]
Curr Hematol Malig Rep (2012) 7:133–143 135
bone marrow transplant and transgenic models of this
disease [26]. Several studies demonstrated that IKZF1
deletions are significantly associated with an increased
relapse rate and adverse events and are correlated with
poor outcome in patients with Ph+ ALL [27–29]. Alter-
ation of IKZF1 is also associated with poor outcome in
BCR-ABL1-negative ALL [27, 29–31], where this asso-
ciation is independent of commonly used risk stratifica-
tion features such as age, sex, white cell count, and
levels of minimal residual disease (MRD). IKZF1 dele-
tions and nonsense mutations identified at diagnosis are
preserved at relapse [27] and may be used for highly
sensitive MRD tests in addition to the repertoire of
MRD markers currently available for monitoring MRD
in ALL [32]. Importantly, high-risk BCR-ABL1 negative
ALL cases with deletion of IKZF1 and poor outcome
have a gene expression profile significantly similar to
that of Ph+ALL (“BCR-ABL1-like” ALL) [29, 33], sug-
gesting that these cases may harbor alternative genetic
events leading to aberrant activation of tyrosine kinase
signaling pathways similar to those downstream of
BCR-ABL1.
PAX5 PAX5 encodes a transcription factor known as B-cell-
specific activator protein, that plays a key role in B-cell
commitment by activating essential components of B-cell
receptor signaling and repressing the transcription of genes
necessary for T-lymphopoiesis [34]. By SNP arrays mono-
allelic deletion of PAX5 has been observed in about 30 % of
both children and adults with B-ALL, resulting in loss of
Pax5 protein expression or in the production of a Pax5
isoform lacking the DNA binding domain and/or transcrip-
tional regulatory domain [5, 17]. Inactivating point muta-
tions in PAX5 are also observed (7–30 %) as well as
chromosomal translocations involving multiple partners
such as ETV6, ENL, FOXP1, ZNF521, PML, C20ORF112,
AUTS2, JAK2, POM121, HIPK1, DACH1, LOC392027,
SLCO1B3, ASXL1, and KIF3B [5, 35, 36]. In these rear-
rangements the DNA binding paired domain of PAX5 and/or
a variable amount of the C-terminal trans-activating
domains are fused to functional domains of the partner
genes, resulting in a loss of Pax5 function rather than in a
gain of functional elements. Alterations of PAX5 have been
demonstrated to not influence treatment outcome [17, 29].
Genetic Alterations in Tumor Suppressors Genes
CDKN2A/B The CDKN2A/B locus is particularly notewor-
thy since it encodes for the INK4-class cyclin dependent
kinase inhibitors p15INK4B, p16INK4A and for p14ARF, which
inhibits MDM2’s E3 ligase activity stabilizing p53. Alter-
ations have been demonstrated to frequently occur in all
lymphoid malignancies, with homozygous deletions as the
most frequent mechanism of inactivation [37]. Recently, we
identified CDKN2A and CDKN2B deletion at diagnosis in
29 % and 25 % of BCR-ABL1-positive ALL patients, re-
spectively. Deletions were predominantly monoallelic and
in more than half of cases the minimal overlapping region of
the lost area included a large number of genes. The detection
rate of CDKN2A/ARF loss increased at relapse compared to
diagnosis [18•]. The association with prognosis is still con-
troversial. Some studies reported a correlation of CDKN2A/
B deletion with poor prognosis, whereas others show no
correlation [38]. Confirming previous findings from mice
models [39], we demonstrated that deletions of CDKN2A/B
are significantly associated with higher white blood count
and poor outcome in terms of overall survival, disease-free
survival, and cumulative incidence of relapse in adult BCR-
ABL1-positive ALL [18•].
Deregulated Expression of CRLF2 Four independent
groups in late 2009 and early 2010 have identified that up
to 50 % of BCR-ABL1-like ALL cases have dysregulated
expression of CRLF2, the gene encoding the cytokine
receptor-like 2 factor, also known as thymic stromal lym-
phopoietin receptor [40–43]. CRLF2 has a role in T-
lymphoid and dendritic cell development and is involved
in inflammation and allergic responses [44]. Although it
also mediates B-cell precursor proliferation and survival,
its role in B-lymphoid neoplasms needs to be understood
[45]. CRLF2 rearrangements include a translocation of
CRLF2, which is located at the pseudoautosomal region 1
(PAR1) of chromosome Xp/Yp, into the immunoglobulin
heavy chain locus at chromosome 14q or a focal PAR1
deletion proximal of CRLF2 that results in a novel
fusion P2RY8-CRLF2 [40–43]. Less commonly, a mis-
sense mutation in exon 6, F232C, results in constitutive
CRLF2 dimerization [43]. All these events result in
overexpression of full-length CRLF2 on the surface of
leukemic cells harboring the genetic alterations, provid-
ing a cell-surface marker amenable to detection by flow
cytometry for clinical diagnostic purposes. Overall aber-
rant expression of CRLF2 was found in 12.5 % to 15 %
of B-ALL that lacks typical chromosomal rearrange-
ments, but was not overexpressed in B-ALL cases that
have recurring rearrangements or in other lymphoid
malignancies [40–43]. CRLF2 alteration is seen at low
rates (5–7 %) when all B-ALL cases are grouped to-
gether; however, it is seen in 50–60 % of Down Syn-
drome (DS) associated ALL, suggesting that CRLF2
overexpression is especially relevant to tumorigenesis
in patients with trisomy 21 [41–43]. In high-risk B-
ALL, rearrangements of CRLF2 are frequently found
together with IKZF1 alterations and activating mutations
in JAK1 and JAK2, most commonly at or near R683 in
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the pseudokinase domain of JAK2 [40–42], and are associated
with very poor outcome [46, 47]. Therapeutically important,
JAK2mutant-CRLF2–mediated andCRLF2mutant–mediated
transformation are sensitive to JAK inhibition in vitro,
suggesting that ALL patients with CRLF2 overexpression
may benefit from future kinase inhibitor approaches [41].
Intrachromosomal Amplification of Chromosome 21 Intra-
chromosomal amplification of chromosome 21 (iAMP21)
occurs at an incidence up to 2 % in older children with B-
cell precursor ALL. iAMP21 was originally identified as a
consequence of routine screening for the presence of the
ETV6-RUNX1 fusion by FISH [48] and is defined by at least
three copies of the RUNX1 gene, commonly concomitant
with deletion of the subtelomeric regions of chromosome
21. Recently, the common region of amplification on chro-
mosome 21 was better refined to a 5.1-Mb region that
included RUNX1, miR-802, and genes mapping to the
DS critical region. Recurrent abnormalities affecting
IKZF1 (22 %), CDKN2A/B (17 %), PAX5 (8 %),
ETV6 (19 %), and RB1 (37 %) and secondary to chro-
mosome 21 rearrangements were identified [49]. iAMP21 has
been shown to be linked to a dismal outcome when patients
are treated with standard therapy, because it is associated with
an increased risk of both early and late relapses [50, 51].
Prognostic Factors Based on Conventional
and Next-Generation Sequencing Technologies
Whole genome/exome-sequencing approaches have been
demonstrated to provide a comprehensive view of the
landscape of genetic alterations in leukemia identifying
crucial markers for diagnosis, risk-stratification, and po-
tentially novel target therapies. Screening for BCR-ABL1
mutations in Philadelphia-positive ALL allows to iden-
tify patients who may benefit from second-generation
TKIs or from novel compounds targeting the T315I
mutation [52]. An extensive Sanger resequencing of
120 candidate cancer genes in diagnostic leukemia sam-
ples from 187 children and adolescents with high-risk
B-ALL treated with augmented post-induction chemo-
therapy on the Children’s Oncology Group P9906 pro-
tocol and integrated analysis with genome-wide CNAs
and gene expression profiles revealed recurrent somatic
alterations in key signaling pathways, including B-cell
development/differentiation (68 %), TP53/RB tumor sup-
pressor pathway (54 %), Ras signaling (50 %), and
Janus kinases (11 %). The frequency of mutations with-
in the four major pathways varied markedly across
genetic subtypes with a striking association of B-cell
development/differentiation and JAK2 mutations with
leukemias expressing a BCR-ABL1-like gene expression
profile and of Ras signaling pathway mutations with
cases defined by a distinct gene expression profile cou-
pled with focal ERG deletion [53]. For most of these
genes the prognostic impact remains to be determined,
but they highlighted important new therapeutic targets
for selected patient subsets. The landscape of genetic
alterations in B-ALL was extended by the identification
of loss-of-function mutations (either deletions or se-
quence mutations) of CREBBP, encoding the transcrip-
tional coactivator and histone acetyltransferase CREB-
binding protein or CBP, in 19 % of relapsed samples
from children with B-cell progenitor ALL [54•]. Func-
tionally, the mutations impair histone acetylation and
transcriptional regulation of CREBBP targets, including
glucocorticoid responsive genes, likely influencing treat-
ment responsiveness in ALL. CREBBP mutations are
preserved at relapse when present at diagnosis, acquired at
relapse but occurring in minor subclones at diagnosis, or
reduplicated to homozygosity at relapse when heterozygous
at diagnosis [54•]. Although the prognostic impact remains to
be determined, the observation that the CREBBP mutations
impair regulation of glucocorticoid-responsive genes, and that
the mutations are selected for at relapse, suggests that these
alterations may influence the likelihood of relapse. Therefore,
novel therapeutic approaches, such as histone deacetylase
inhibitors (HDAC) [55], directed at modulating protein acet-
ylation may be useful in high-risk ALL. Recently, new mo-
lecular prognostic markers have been identified. The analysis
of 265 first-relapse patients enrolled in the German Acute
Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster
2002 (ALL-REZ BFM 2002) trial for sequence and copy
number alterations of the TP53 gene, by using direct sequenc-
ing and multiplex ligation-dependent probe amplification,
identified copy number and sequence alterations of TP53 in
12.4 % of B-cell precursor ALL samples [56]. In more than
half of cases (54 %) TP53 alterations were gained at
relapse. Mutations were strikingly associated with non-
response to chemotherapy and poor event-free survival
and overall survival rates, allowing the identification of
patients at high risk of treatment failure. To overcome
the limits of conventional Sanger sequencing whole
exome and transcriptome NGS approaches have been
subsequently pursued in two pediatric ETV6-RUNX1
(TEL-AML1) positive ALL [57] and in an adult patient
with BCR-ABL1 positive ALL [58], respectively. Both
studies identified novel somatic mutations, some of
them occurred in genes previously described to be mu-
tated in other types of cancer, but none was found to be
recurrent in an extended series of ALL samples. Although the
true pathogenetic significance of the mutations must await
future functional evaluations, these studies provided a first
estimate of the mutational burden of ETV6-RUNX1 and
BCR-ABL1-positive ALLs.
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T-Progenitor Acute Lymphoblastic Leukemia
Prognostic Factors Based on Cytogenetics
T-ALL is a malignant disorder of T-cell lymphoid progenitor
cells that affects 15 % of children and 25 % of adults with
ALL. Structural chromosomal aberrations are identified in
approximately 50 % of cases and frequently involve the
juxtaposition of strong promoter and enhancer elements
from T-cell receptor (TCR) genes with transcription
factor genes as consequence of an illegitimate event
during V(D)J recombination in normal T-cell development.
This leads to the aberrant expression of the fusion partners
resulting in thymocytes differentiation block at various
stages of maturation.
TCR Gene Rearrangements
The most common rearrangements include TCR alpha/delta
chain at 14q11.2, TCR beta chain at 7q34, and TCR gamma
chain at 7p14. With few exceptions, the involved gene on
the partner chromosome encodes a cell cycle inhibitor or a
transcription factor whose expression is deregulated or acti-
vated as a result of the rearrangement. TAL1 (1p32) is
ectopically expressed in T-ALL as consequence of t(1;14)
(p32;q11) [59] (3 % in childhood T-ALL) and more fre-
quently as a consequence of the intrachromosomal deletion
resulting in SIL-TAL1 fusion gene, while LYL1 (19p13),
TAL2 (9q32), and BHLH1 (21q22) are up-regulated in the
rare translocations t(7;19)(q34;p13), t(7;9)(q34;q32), and t
(14;21)(q11;q22), respectively. Their aberrant expression
may contribute to leukemia through the formation of heter-
odimers with class I basic helix-loop-helix members that
regulate T-cell specific genes, with consequent differentia-
tion and proliferation impairment. LIM domain only genes
LMO1 (11p15) and LMO2 (11p13) are involved in t(11;14)
(p15;q11) and t(11;14)(p13;q11) with TCR alpha/delta loci
and in translocations with TCR beta. LMO abnormal ex-
pression associates with deregulation of LYL1 and TAL1,
even in absence of specific translocations [60]. The homeo-
box (HOX) genes are a highly conserved family of tran-
script ion factors that play an important role in
morphogenesis during embryonic development and in nor-
mal hemopoiesis [61]. The inv(7)(p15q34) and t(7;7)(p15;
q34) bring the TCR beta regulatory elements in the vicinity
of the HOXA genes cluster disrupting the normal regulatory
elements of the cluster with subsequent up-regulation, espe-
cially of HOXA9, HOXA10, and HOXA11 [62, 63]. TLX1
(HOX11) is expressed at high level in more than 30 % of
adult T-ALL as consequence of t(10;14)(q24;q11) and t
(7;10)(q34;q24), while TLX3 (HOX11L2) is involved in t
(5;14)(q35;q32) with the fusion partner BCL11B in about
20 % of children and 4 % of adults [64]. Additional genes
rarely involved in TCR loci rearrangements are LCK [65],
CCND2 [66], and IRS4 [67].
Non-TCR Loci
A variety of cytogenetic abnormalities can occur in T-cell
ALL that do not involve the TCR loci. These include del
(6q), t(11q23) (MLL gene), t(14q32), trisomy 8, and t
(10;11). A favorable prognostic correlation has been
assessed for t(10;14), which is extremely rare in adult
patients, and more frequent in the pediatric subset. Trisomy
of chromosome 8 and monosomy of chromosome 7 usually
carry a bad prognosis [68]. The cryptic deletion del(9)
(q34.11q34.13) results in the SET-NUP214 fusion product,
which transcriptionally activates specific members of the
HOXA cluster maybe contributing to T-ALL pathogenesis
by the inhibition of T-cell maturation [69]. The ABL1 cyto-
plasmic tyrosine kinase plays a role in T-cell signaling,
leading to the induction of IL-2 production and proliferation
following TCR activation [70]. ABL1 fusion genes can be
identified in about 8 % of T-ALL. EML1-ABL1 fusion due
to a cryptic t(9;14)(q34;q32), BCR-ABL1 t(9;22)(q34;q11),
and ETV6-ABL1 t(9;12)(q34;p13) are seldom reported chi-
meric genes in T-ALL, although if frequent in other hema-
tologic malignancies. In contrast, the most frequent and
strictly associated alteration with T-ALL is the NUP214-
ABL1 fusion identified in 6 % of cases, in both children and
adults, also if it is not clear its prognostic relevance [71].
JAK2 resulted constitutively activated in the rare t(9;12)
(p24;p13) encoding ETV6-JAK2 fusion oncoprotein, while
JAK1 is widely mutated in adult T-ALL (18 %) and less in
children (3 %), and associates with a poor response to
therapy [72]. Finally, a recent study identified a novel fusion
partner of ETV6 in one T-ALL patient, harboring ETV6-
ARNT t(1;12)(q21;p13) [73].
Prognostic Factors Based on Genomic Profiling
On the basis of gene expression profiling, T-ALL cases can
be classified into major subgroups that are indicative of
leukemic arrest at specific stages of normal thymocyte de-
velopment (HOX11+ early cortical thymocytes; LYL1+ early
pro-T thymocytes; TAL1+ late cortical thymocytes) and have
clinical relevance, because they are associated with a favor-
able or worse prognosis [60]. Using SNP array platforms,
many novel genomic alterations have recently been identi-
fied, including focal deletions of RB1 [5], duplications of the
proto-oncogene MYB [5, 74], deletion of 9p21.2 in more
than 70 % of patients [75], deletion and mutation of PTEN
[5, 76], and deletion or mutation of the U3 ubiquitin ligase
FBXW7 [77, 78]. Thus far, mutations of NOTCH1 and
FBXW7 have generally been associated with a favorable
prognosis [79]. NOCTH1 role in leukemogenesis was
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initially identified in the rare chromosomal translocation t
(7;9)(q34;q34.3) that fuses the intracellular form of
NOTCH1 to the TCR beta and leads to the expression of
TAN1, a truncated and constitutively activated form of
NOTCH1; subsequently, activating or loss of function muta-
tions has been identified in more than 50 % of T-ALL cases,
representing the most common alteration in T-ALL. The
high frequency of NOTCH1 mutations in T-ALL has
sparked an interest in the development of anti-NOTCH1
targeted therapies for the treatment of T-ALL. Other mutated
genes in T-ALL are WT1, NRAS, the negative regulator of
the RAS pathway, NF1 that is inactivated because of dele-
tions or mutations [80], and rarely FLT3 [81, 82] and
PTPN2 [83], that are affected by activating mutations and
focal deletions, respectively. All these genes play crucial
roles as regulators and alterations in their function may
affect critically different signal transduction pathways. Of
note, identification of 6q15-16.1 deletion containing CAS-
P8AP2 gene represents a novel prognostic factor that
defines a high-risk group (Table 2) [84].
Prognostic Factors Based on Next-Generation Sequencing
Technology
Using exon capture of chromosome X a recent study by Van
Vlierberghe and colleagues [85] identified inactivating muta-
tions of the X-linked plant homeodomain finger 6 (PHF6) in
16 % of pediatric and 38 % of adult T-ALL cases. PHF6
mutations were almost exclusively found in male and were
associated with leukemias driven by aberrant expression of
TLX1 and TLX3. Although the prognostic significance remains
to be determined, PHF6 has emerged as a new X-linked tumor
suppressor in T-ALL. Recently, the application of whole-
genome sequencing (WGS) to the characterization of “early
T-cell precursor” (ETP) ALL, that comprises up to 15 % of T-
ALL and is associated with a high risk of treatment failure, has
provided potential new molecular targets for therapy [86••].
Zhang and colleagues [86••] performed WGS of 12 ETPALL
cases identifying activating mutations in genes regulating cy-
tokine receptor and RAS signaling, such as NRAS, KRAS,
FLT3, IL7R, JAK3, JAK1, SH2B3, and BRAF (67 %), inacti-
vating lesions disrupting hematopoietic development, such as
GATA3, ETV6, RUNX1, IKZF1, and EP300 (58 %), and
histone-modifying genes, such asEZH2, EED, SUZ12, SETD2,
and EP300 (48 %). Moreover, they identified new targets of
recurrent mutation inDNM2, ECT2L, and RELN genes. Impor-
tantly, the gene expression profile of ETPALL resulted similar
to that of normal and myeloid leukemia hematopoietic stem
cells, suggesting the possibility that myeloid-directed therapies
might improve the poor outcome of ETPALL.
Conclusions
Thanks to the use of SNP microarray-based technology,
extensive candidate gene sequencing, and whole genome/
Table 2 Novel recurring genetic alterations occurring in T-progenitor ALL and their correlation with outcome
Gene name Alteration Frequency Prognosis Reference
NOTCH1 Sequence mutations ~50 % of T-ALL Associated with favorable outcome
in children
[89–92]
FBXW7 Sequence mutations ~20 % of T-ALL Associated with favorable outcome
in children
[78, 91, 92]
PTEN Deletions or sequence mutations 6–8 % of T-ALL Associated with poor response to
chemotherapy and resistance to
pharmacological inhibition of NOTCH1
[76, 93]
CDKN2A/B Deletions 30–70 % of T-ALL Associated with poor outcome in adult
and children T-ALL
[94, 95]
CDKN1A Deletions or sequence mutations 12 % of T-ALL To be investigated [84, 96]
6q15-16.1 Deletion 12 % of T-ALL Associated with poor outcome [84]
PHF6 Deletions or sequence mutations 16 % of pediatric T-ALL cases;
38 % of adult T-ALL cases
Associated with reduced overall survival [85]
WT1 Frameshift mutations 13 % of pediatric T-ALL cases;
12 % of adult T-ALL cases
No association with outcome [97, 98]
LEF1 Focal deletions or sequence
mutations
15 % of pediatric T-ALL cases Associated with younger age and a
trend toward a better overall survival
[99]
JAK1 Sequence mutations 18 % of adult T-ALL cases Associated with reduced disease-free
survival and overall survival
[72]
FLT3 Internal tandem duplication 4 % of adult T-ALL cases; 3 %
of pediatric T-ALL cases
No association with outcome [81, 82]
PTPN2 Deletion 6 % of T-ALL Down-regulation of PTPN2 expression
results in prolonged survival of ALL-SIL
cells after imatinib treatment
[100]
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exome/transcriptome NGS approaches, novel and recurring
lesions have been identified in B and T-ALL. The identifi-
cation of these alterations allowed a better classification of
leukemia patients in subgroups according to specific genetic
lesions (eg, BCR-ABL1 like subgroup), provided new
markers for risk-assessment and/or for monitoring minimal
residual disease (eg, IKZF1, CRLF2, TP53), and highlighted
novel therapeutic approaches (eg, inhibitors of JAK2,
HDAC, and NOTCH1). However, much remains to be in-
vestigated. From the biological prospective, whole exome/
transcriptome NGS approaches will provide a comprehen-
sive view of the complexity of genetic alterations in ALL,
identifying genes and pathways relevant for the establish-
ment of the leukemia clone and/or for the disease recurrence
and responsible for responsiveness to therapy. From the
clinical prospective, all these findings should be integrated
into the clinic, providing new prognostic markers and novel
targets for tailored therapies.
Acknowledgments Supported by European LeukemiaNet, AIL,
AIRC, Fondazione Del Monte di Bologna e Ravenna, FIRB 2006,
Ateneo RFO grants, Project of integreted program (PIO), Programma
di Ricerca Regione—Università 2007–2009.
Disclosure No potential conflicts of interest relevant to this article
were reported.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children
with acute lymphoblastic leukemia: results of Total Therapy
Study XIIIB at St Jude Children’s Research Hospital. Blood.
2004;104:2690–6.
2. Bassan R. Evolving strategies for the management of high-risk
adult acute lymphoblastic leukemia. Haematologica. 2005;90:1299.
3. Andreasson P, Schwaller J, Anastasiadou E, et al. The expression
of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transfor-
mation of hematopoietic cell lines in vitro or the induction of
hematologic disease in vivo. Cancer Genet Cytogenet.
2001;130:93–104.
4. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances
oncogenicity and limits imatinib response in mouse models of
Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad
Sci USA. 2006;103:6688–93.
5. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis
of genetic alterations in acute lymphoblastic leukaemia. Nature.
2007;446:758–64.
6. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an
independent prognostic factor in adult acute lymphoblastic leu-
kemia (ALL): analysis of cytogenetic data from patients treated
on the Medical Research Council (MRC) UKALLXII/Eastern
Cooperative Oncology Group (ECOG) 2993 trial. Blood.
2007;109:3189–97.
7. A Collaborative Study of the Group Francais de Cytogenetique
Hematologique. Cytogenetic abnormalities in adult acute lym-
phoblastic leukemia: correlations with hematologic findings out-
come. Blood. 1996;87:3135–42.
8. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia.
Lancet. 2008;371:1030–43.
9. Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in
Philadelphia-positive leukemia patients and the presence or the
selection of mutations at residues 315 and 317 in the BCR-ABL
kinase domain. Haematologica. 2007;92:401–4.
10. Devaraj PE, Foroni L, Janossy G, et al. Expression of the E2A-
PBX1 fusion transcripts in t(1;19)(q23;p13) and der(19)t(1;19) at
diagnosis and in remission of acute lymphoblastic leukemia
with different B lineage immunophenotypes. Leukemia.
1995;9:821–5.
11. Foa R, Vitale A, Mancini M, et al. E2A-PBX1 fusion in adult
acute lymphoblastic leukaemia: biological and clinical features.
Br J Haematol. 2003;120:484–7.
12. Romana SP, Poirel H, Leconiat M, et al. High frequency of t
(12;21) in childhood B-lineage acute lymphoblastic leukemia.
Blood. 1995;86:4263–9.
13. Raimondi SC, Pui CH, Hancock ML, et al. Heterogeneity of
hyperdiploid (51–67) childhood acute lymphoblastic leukemia.
Leukemia. 1996;10:213–24.
14. Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct
subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br
J Haematol. 2004;125:552–9.
15. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and
molecular characterization of recurrent genomic deletions on
7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-
positive acute lymphoblastic leukemia patients: on behalf of
Gruppo Italiano Malattie Ematologiche dell’Adulto Acute
Leukemia Working Party (GIMEMA AL WP). Blood.
2009;114:2159–67.
16. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. High-
resolution genomic profiling of childhood ALL reveals novel
recurrent genetic lesions affecting pathways involved in lympho-
cyte differentiation and cell cycle progression. Leukemia.
2007;21:1258–66.
17. Iacobucci I, Lonetti A, Paoloni F, et al. The PAX5 gene is frequently
rearranged in BCR-ABL1-positive acute lymphoblastic leukemia
but is not associated with outcome A report on behalf of the
GIMEMA Acute Leukemia Working Party. Haematologica.
2010;95:1683–90.
18. • Iacobucci I, Ferrari A, Lonetti A, et al. CDKN2A/B alterations
impair prognosis in adult BCR-ABL1-positive acute lymphoblastic
leukemia patients. Clin Cancer Res. 2011;17:7413–23. In adult
BCR-ABL1 positive ALL CDKN2A/B deletions represent a frequent
event and they are frequently acquired during leukemia progres-
sion. Deletions are significantly associated with poor outcomes in
terms of overall survival, disease free-survival, and cumulative
incidence of relapse.
19. Trageser D, Iacobucci I, Nahar R, et al. Pre-B cell receptor-
mediated cell cycle arrest in Philadelphia chromosome-positive
acute lymphoblastic leukemia requires IKAROS function. J Exp
Med. 2009;206:1739–53.
20. Diouf B, Cheng Q, Krynetskaia NF, et al. Somatic deletions of
genes regulating MSH2 protein stability cause DNA mismatch
repair deficiency and drug resistance in human leukemia cells.
Nat Med. 2011;17:1298–303.
140 Curr Hematol Malig Rep (2012) 7:133–143
21. Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is
required for the development of all lymphoid lineages. Cell.
1994;79:143–56.
22. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lympho-
blastic leukaemia is characterized by the deletion of Ikaros.
Nature. 2008;453:110–4.
23. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced
oncogenic Ikaros isoforms in Philadelphia-positive acute
lymphoblastic leukemia patients treated with tyrosine kinase
inhibitors: implications for a new mechanism of resistance.
Blood. 2008;112:3847–55.
24. Cazzaniga G, van Delft FW, Lo Nigro L, et al. Developmental
origins and impact of BCR-ABL1 fusion and IKZF1 deletions in
monozygotic twins with Ph+acute lymphoblastic leukemia.
Blood. 2011;118:5559–64.
25. Tonnelle C, Dijon M, Moreau T, et al. Stage specific over-
expression of the dominant negative Ikaros 6 reveals distinct role
of Ikaros throughout human B-cell differentiation. Mol Immunol.
2009;46:1736–43.
26. Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the
IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-
ABL in a transgenic model of acute lymphoblastic leukemia.
Leukemia. 2010;24:1200–4.
27. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 dele-
tions predict relapse in uniformly treated pediatric precursor B-
ALL. Leukemia. 2010;24:1258–64.
28. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions
in BCR-ABL1-positive acute lymphoblastic leukemia are associated
with short disease-free survival and high rate of cumulative incidence
of relapse: a GIMEMAALWP report. J ClinOncol. 2009;27:5202–7.
29. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis
in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80.
30. Waanders E, van der Velden VH, van der Schoot CE, et al.
Integrated use of minimal residual disease classification and
IKZF1 alteration status accurately predicts 79 % of relapses in
pediatric acute lymphoblastic leukemia. Leukemia; 2010.
31. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor
prognosis in children with B-cell progenitor acute lymphoblastic leuke-
mia: a multicenter analysis in Taiwan. Cancer Sci. 2011;102:1874–81.
32. Venn NC, van der Velden VH, de Bie M, et al. Highly sensitive
MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion.
Leukemia; 2011.
33. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A
subtype of childhood acute lymphoblastic leukaemia with poor
treatment outcome: a genome-wide classification study. Lancet
Oncol. 2009;10:125–34.
34. Busslinger M. Transcriptional control of early B cell develop-
ment. Annu Rev Immunol. 2004;22:55–79.
35. Familiades J, Bousquet M, Lafage-Pochitaloff M, et al. PAX5
mutations occur frequently in adult B-cell progenitor acute lym-
phoblastic leukemia and PAX5 haploinsufficiency is associated
with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL
study. Leukemia; 2009.
36. Nebral K, Denk D, Attarbaschi A, et al. Incidence and diversity of
PAX5 fusion genes in childhood acute lymphoblastic leukemia.
Leukemia. 2009;23:134–43.
37. Faderl S, Estrov Z, Kantarjian HM, et al. The incidence of chromo-
some 9p21 abnormalities and deletions of tumor suppressor genes
p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lympho-
blastic leukemia. Cytokines Cell Mol Ther. 1999;5:159–63.
38. Heyman M, Rasool O, Borgonovo Brandter L, et al. Prognostic
importance of p15INK4B and p16INK4 gene inactivation in child-
hood acute lymphocytic leukemia. J Clin Oncol. 1996;14:1512–20.
39. Notta F, Mullighan CG, Wang JC, et al. Evolution of human
BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature.
2011;469:362–7.
40. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of
cytokine receptor gene, CRLF2, is involved in lymphoid trans-
formation in B-cell precursor acute lymphoblastic leukemia.
Blood. 2009;114:2688–98.
41. Mullighan CG, Collins-Underwood JR, Phillips LA, et al.
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-
associated acute lymphoblastic leukemia. Nat Genet. 2009;
41:1243–6.
42. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome
acute lymphoblastic leukemia, a highly heterogeneous disease in
which aberrant expression of CRLF2 is associated with mutated
JAK2: a report from the International BFM Study Group. Blood.
2010;115:1006–17.
43. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies
CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc
Natl Acad Sci USA. 2010;107:252–7.
44. Liu YJ. TSLP in epithelial cell and dendritic cell cross talk. Adv
Immunol. 2009;101:1–25.
45. Levin SD, Koelling RM, Friend SL, et al. Thymic stromal lym-
phopoietin: a cytokine that promotes the development of IgM+B
cells in vitro and signals via a novel mechanism. J Immunol.
1999;162:677–83.
46. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of
CRLF2 is associated with mutation of JAK kinases, alteration of
IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-
progenitor acute lymphoblastic leukemia. Blood. 2010;115:5312–21.
47. Cario G, Zimmermann M, Romey R, et al. Presence of the
P2RY8-CRLF2 rearrangement is associated with a poor prognosis
in non-high-risk precursor B-cell acute lymphoblastic leukemia in
children treated according to the ALL-BFM 2000 protocol. Blood.
2010;115:5393–7.
48. Harrison CJ, Moorman AV, Barber KE, et al. Interphase molec-
ular cytogenetic screening for chromosomal abnormalities of
prognostic significance in childhood acute lymphoblastic leukae-
mia: a UK Cancer Cytogenetics Group Study. Br J Haematol.
2005;129:520–30.
49. Rand V, Parker H, Russell LJ, et al. Genomic characterization impli-
cates iAMP21 as a likely primary genetic event in childhood B-cell
precursor acute lymphoblastic leukemia. Blood. 2011;117:6848–55.
50. Moorman AV, Richards SM, Robinson HM, et al. Prognosis of
children with acute lymphoblastic leukemia (ALL) and intrachro-
mosomal amplification of chromosome 21 (iAMP21). Blood.
2007;109:2327–30.
51. Attarbaschi A, Mann G, Panzer-Grumayer R, et al. Minimal
residual disease values discriminate between low and high re-
lapse risk in children with B-cell precursor acute lymphoblas-
tic leukemia and an intrachromosomal amplification of
chromosome 21: the Austrian and German acute lymphoblas-
tic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J
Clin Oncol. 2008;26:3046–50.
52. Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute
lymphoblastic leukemia patients already harbor BCR-ABL ki-
nase domain mutations at low levels at the time of diagnosis.
Haematologica. 2011;96:552–7.
53. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are
frequently mutated in high-risk childhood acute lymphoblastic
leukemia: a report from the Children’s Oncology Group. Blood.
2011;118:3080–7.
54. • Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations
in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235–
9. Mutations of CREBBP, occurring 8.3 % of relapse B-ALL, are
either present at diagnosis or acquired at relapse, and resulted in
truncated alleles or deleterious substitutions in conserved residues
of the histone acetyltransferase domain that impair histone acety-
lation and transcriptional regulation of CREBBP targets, including
glucocorticoid responsive genes.
Curr Hematol Malig Rep (2012) 7:133–143 141
55. Bolden JE, PeartMJ, Johnstone RW.Anticancer activities of histone
deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–84.
56. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions
of the TP53 gene predict nonresponse to treatment and poor
outcome in first relapse of childhood acute lymphoblastic leuke-
mia. J Clin Oncol. 2011;29:3185–93.
57. Lilljebjorn H, Rissler M, Lassen C, et al. Whole-exome
sequencing of pediatric acute lymphoblastic leukemia.
Leukemia; 2011.
58. Iacobucci I, Ferrarini A, Sazzini M, et al. Application of the
whole transcriptome shotgun sequencing approach to the study
of philadelphia-positive acute lymphoblastic leukemia. Blood
Cancer Journal; 2012.
59. Carroll AJ, Crist WM, Link MP, et al. The t(1;14)(p34;q11) is
nonrandom and restricted to T-cell acute lymphoblastic leukemia:
a Pediatric Oncology Group study. Blood. 1990;76:1220–4.
60. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression
signatures define novel oncogenic pathways in T cell acute lym-
phoblastic leukemia. Cancer Cell. 2002;1:75–87.
61. van Oostveen J, Bijl J, Raaphorst F, et al. The role of homeobox
genes in normal hematopoiesis and hematological malignancies.
Leukemia. 1999;13:1675–90.
62. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are
included in genetic and biologic networks defining human acute
T-cell leukemia (T-ALL). Blood. 2005;106:274–86.
63. Speleman F, Cauwelier B, Dastugue N, et al. A new recurrent
inversion, inv(7)(p15q34), leads to transcriptional activation of
HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic
leukemias. Leukemia. 2005;19:358–66.
64. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new
recurrent and specific cryptic translocation, t(5;14)(q35;q32), is
associated with expression of the Hox11L2 gene in T acute
lymphoblastic leukemia. Leukemia. 2001;15:1495–504.
65. Tycko B, Smith SD, Sklar J. Chromosomal translocations joining
LCK and TCRB loci in human T cell leukemia. J Exp Med.
1991;174:867–73.
66. Clappier E, Cuccuini W, Cayuela JM, et al. Cyclin D2 dysregu-
lation by chromosomal translocations to TCR loci in T-cell acute
lymphoblastic leukemias. Leukemia. 2006;20:82–6.
67. Karrman K, Kjeldsen E, Lassen C, et al. The t(X;7)(q22;q34) in
paediatric T-cell acute lymphoblastic leukaemia results in over-
expression of the insulin receptor substrate 4 gene through ille-
gitimate recombination with the T-cell receptor beta locus. Br J
Haematol. 2009;144:546–51.
68. Rowe JM. Prognostic factors in adult acute lymphoblastic leu-
kaemia. Br J Haematol. 2010;150:389–405.
69. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent
SET-NUP214 fusion as a new HOXA activation mechanism in
pediatric T-cell acute lymphoblastic leukemia. Blood.
2008;111:4668–80.
70. Zipfel PA, Zhang W, Quiroz M, et al. Requirement for Abl
kinases in T cell receptor signaling. Curr Biol. 2004;14:1222–31.
71. Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute
lymphoblastic leukemia. Genes Chromosomes Cancer.
2010;49:299–308.
72. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1
mutations in adult acute lymphoblastic leukemia. J Exp Med.
2008;205:751–8.
73. Otsubo K, Kanegane H, Eguchi M, et al. ETV6-ARNT fusion in a
patient with childhood T lymphoblastic leukemia. Cancer Genet
Cytogenet. 2010;202:22–6.
74. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al.
Duplication of the MYB oncogene in T cell acute lymphoblastic
leukemia. Nat Genet. 2007;39:593–5.
75. Hebert J, Cayuela JM, Berkeley J, et al. Candidate tumor-
suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B)
display frequent homozygous deletions in primary cells from T-
but not from B-cell lineage acute lymphoblastic leukemias.
Blood. 1994;84:4038–44.
76. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN
induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat
Med. 2007;13:1203–10.
77. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally
unstable mouse tumours have genomic alterations similar to
diverse human cancers. Nature. 2007;447:966–71.
78. O’Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic
cells mediate NOTCH pathway activation and resistance to
gamma-secretase inhibitors. J Exp Med. 2007;204:1813–24.
79. Ferrando A. NOTCH mutations as prognostic markers in T-ALL.
Leukemia. 2010;24:2003–4.
80. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al.
Leukemia-associated NF1 inactivation in patients with pediatric
T-ALL and AML lacking evidence for neurofibromatosis. Blood.
2008;111:4322–8.
81. Van Vlierberghe P, Meijerink JP, Stam RW, et al. Activating FLT3
mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic
leukemias. Blood. 2005;106:4414–5.
82. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3
mutations in CD117/KIT(+) T-cell acute lymphoblastic leuke-
mias. Blood. 2004;104:558–60.
83. Kleppe M, Lahortiga I, El Chaar T, et al. Deletion of the protein
tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic
leukemia. Nat Genet. 2010;42:530–5.
84. Remke M, Pfister S, Kox C, et al. High-resolution genomic
profiling of childhood T-ALL reveals frequent copy-number
alterations affecting the TGF-beta and PI3K-AKT pathways and
deletions at 6q15–16.1 as a genomic marker for unfavorable early
treatment response. Blood. 2009;114:1053–62.
85. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6
mutations in T-cell acute lymphoblastic leukemia. Nat Genet.
2010;42:338–42.
86. •• Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early
T-cell precursor acute lymphoblastic leukaemia. Nature.
2012;481:157–63. Zhang and colleagues performed whole genome
sequencing of 12 ETPALL cases identifying activating mutations in
genes regulating cytokine receptor and RAS signaling (67 %),
inactivating lesions disrupting hematopoietic development (58 %),
and histone-modifying genes (48 %). Gene expression profile of
ETP ALL resulted similar to that of normal and myeloid leukemia
hematopoietic stem cells, suggesting the possibility that myeloid-
directed therapies might improve the poor outcome of ETPALL.
87. Sulong S, Moorman AV, Irving JA, et al. A comprehensive
analysis of the CDKN2A gene in childhood acute lymphoblastic
leukemia reveals genomic deletion, copy number neutral loss of
heterozygosity, and association with specific cytogenetic sub-
groups. Blood. 2009;113:100–7.
88. Mullighan CG, Williams RT, Downing JR, et al. Failure of
CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and
resistance to targeted therapy in acute lymphoblastic leukemia
induced by BCR-ABL. Genes Dev. 2008;22:1411–5.
89. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of
NOTCH1 in human T cell acute lymphoblastic leukemia.
Science. 2004;306:269–71.
90. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations
predict favorable early treatment response and long-term outcome
in childhood precursor T-cell lymphoblastic leukemia. Blood.
2006;108:1151–7.
91. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation
identifies a large subgroup with favorable outcome in adult T-cell
acute lymphoblastic leukemia (T-ALL): a Group for Research on
Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood.
2009;113:3918–24.
142 Curr Hematol Malig Rep (2012) 7:133–143
92. Baldus CD, Thibaut J, Goekbuget N, et al. Prognostic implica-
tions of NOTCH1 and FBXW7 mutations in adult acute T-
lymphoblastic leukemia. Haematologica. 2009;94:1383–90.
93. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of
PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblas-
tic leukemia. Blood. 2009;114:647–50.
94. Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16
genes as a poor-prognosis factor in adult T-cell leukemia. J Clin
Oncol. 1997;15:1778–85.
95. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous
deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in
acute lymphoblastic leukemia and association with adverse
prognostic features. Blood. 1995;85:2685–90.
96. Markaki EA, Stiakaki E, Zafiropoulos A, et al. Mutational analysis
of the cell cycle inhibitor Kip1/p27 in childhood leukemia. Pediatr
Blood Cancer. 2006;47:14–21.
97. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-
ALL. Blood. 2009;114:1038–45.
98. Renneville A, Kaltenbach S, Clappier E, et al. Wilms tumor 1
(WT1) gene mutations in pediatric T-cell malignancies.
Leukemia. 2010;24:476–80.
99. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell
acute lymphoblastic leukemia. Blood. 2010;115:2845–51.
100. Kleppe M, Soulier J, Asnafi V, et al. PTPN2 negatively regulates
oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood.
2011;117:7090–8.
Curr Hematol Malig Rep (2012) 7:133–143 143
